| All | DM | Non-DM | |||
---|---|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | HR (95% CI) | P-value | |
caIMR ≥ 25 | 2.683 (1.343–5.361) | 0.005 | 2.760 (1.066–7.146) | 0.036 | -* |  |
caIMR | -* | Â | -* | Â | -* | Â |
CKD | -* | Â | -* | Â | -* | Â |
Male | -* | Â | -* | Â | -* | Â |
Hypertension | -* | Â | -* | Â | -* | Â |
HbA1c | -* | Â | -* | Â | -* | Â |
Statin | 0.240 (0.088–0.649) | 0.005 | -* |  | 0.163 (0.030–0.898) | 0.037 |
Aspirin | -* |  | -* |  | 0.208 (0.051–0.850) | 0.029 |
P2Y12 receptor antagonist | -* | Â | -* | Â | -* | Â |
LVEF | 0.910 (0.876–0.945) | < 0.001 | 0.935 (0.894–0.978) | 0.003 | 0.883 (0.814–0.958) | 0.003 |